Q3 Results: SBI Card, SBI Life Shares Dip 3%; Gland Pharma Surges 9%

• SBI Card and SBI Life shares dropped over 3% each after their Q3 FY26 results failed to impress D-Street.
• Gland Pharma shares rallied more than 9% to a two-month high following its strong Q3 FY26 performance.
• SBI Card reported a 45% YoY net profit rise to Rs 556.64 crore, but Motilal Oswal cut estimates due to margin contraction.
• SBI Life's net profit increased 5% YoY to Rs 576.74 crore, including an exceptional item; Goldman Sachs maintained a 'Buy' rating.
• Gland Pharma's consolidated net profit jumped 28% YoY to Rs 261.47 crore, driven by strong sales in Europe and the U.S., leading to a Nomura upgrade to 'Buy'.

Why It Matters: Mixed Q3 results lead to divergent stock performances for SBI Card, SBI Life, and Gland Pharma.